However, there were no significant differences in pathologic tumor size between stage I–II CMCs (mean 17 ± 6 mm) and stage IIIA–IIIB CMCs (mean 18 ± 8 mm, p = 0.223), and no significant differences in CK5/6 and EGFR expression between stage I–II CMCs and stage IIIA–IIIB CMCs. The gene discussed is KRT5; the disease is neoplasm.